Tags

Type your tag names separated by a space and hit enter

Treatment of osteoporosis with TheraCyte-encapsulated parathyroid cells: a study in a rat model.
Osteoporos Int. 2006; 17(6):936-41.OI

Abstract

INTRODUCTION

The purpose of this study was to evaluate parathyroid function at monthly intervals following the implantation of TheraCyte-encapsulated live human parathyroid cells into ovariectomized rats and to determine the effect on bone mineral density (BMD) 4 months after ovariectomy (3 months after implantation).

METHODS

Parathyroid tissues were obtained from patients undergoing surgery for secondary hyperparathyroidism. In total, 21 Sprague-Dawley rats divided randomly into three groups were subjected to one of three treatments: (1) implanted with TheraCyte A-encapsulated 4x10(6) live parathyroid cells; (2) implanted with TheraCyte B-encapsulated 4x10(5) live parathyroid cells; (3) a sham operation; the control group. Rats were ovariectomized 1 month prior to the implantation of the TheraCyte. Blood was drawn at the time of implantation and at monthly intervals thereafter for 3 months to check the levels of calcium, phosphorus and intact parathyroid hormone (iPTH). The BMD of the lumbar spine (L1-L5) and of the left femoral bone was measured with dual-energy-X-ray absorptiometry (DEXA) 1 month after ovariectomy and 3 months after implantation of the TheraCyte (4 months after ovariectomy).

RESULTS

We found that the viability ratio of cryopreserved tissues was between 55 and 79% after thawing. In the control group, the BMD of the lumbar spine (L1-L5) had not decreased significantly (p=0.237) nor had the BMD of the left femoral bone increased significantly (p=0.063) 3 months after implantation. In the TheraCyte A group, the BMD of both the lumbar spine (p=0.018) and left femoral bone (p=0.018) had increased significantly 3 months after implantation. In the TheraCyte B group, the BMD of both the lumbar spine (p=0.017) and the left femoral bone (p=0.025) had also increased significantly 3 months after implantation. Serum iPTH levels were higher in the TheraCyte A group than in the TheraCyte B group (p=0.006), and higher in the TheraCyte B group than in the control group (p=0.040). Serum calcium levels were not significantly higher in the TheraCyte group A than in the TheraCyte B group or in the control group. Serum phosphorus levels were not significantly different between the TheraCyte A and TheraCyte B groups.

CONCLUSIONS

Implantation of TheraCyte A-encapsulated 4x10(5) live parathyroid cells and TheraCyte B-encapsulated 4x10(6) cells can increase the BMD of ovariectomized rats within 3 months of implantation. Neither cause high serum calcium and low phosphorus concentrations.

Authors+Show Affiliations

Department of General Surgery, Chang Gung Memorial Hospital at Kaohsiung, Chang Gung University 123, Ta-Pei Road, Niao-Sung Hsiang, Kaohsiung Hsien, Taiwan, Republic of China. choulu@ms4.hinet.netNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16596462

Citation

Chou, F-F, et al. "Treatment of Osteoporosis With TheraCyte-encapsulated Parathyroid Cells: a Study in a Rat Model." Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, vol. 17, no. 6, 2006, pp. 936-41.
Chou FF, Huang SC, Chen SS, et al. Treatment of osteoporosis with TheraCyte-encapsulated parathyroid cells: a study in a rat model. Osteoporos Int. 2006;17(6):936-41.
Chou, F. F., Huang, S. C., Chen, S. S., Wang, P. W., Huang, P. H., & Lu, K. Y. (2006). Treatment of osteoporosis with TheraCyte-encapsulated parathyroid cells: a study in a rat model. Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 17(6), 936-41.
Chou FF, et al. Treatment of Osteoporosis With TheraCyte-encapsulated Parathyroid Cells: a Study in a Rat Model. Osteoporos Int. 2006;17(6):936-41. PubMed PMID: 16596462.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of osteoporosis with TheraCyte-encapsulated parathyroid cells: a study in a rat model. AU - Chou,F-F, AU - Huang,S-C, AU - Chen,S-S, AU - Wang,P-W, AU - Huang,P-H, AU - Lu,K-Y, Y1 - 2006/04/05/ PY - 2005/04/27/received PY - 2006/01/11/accepted PY - 2006/4/6/pubmed PY - 2007/2/21/medline PY - 2006/4/6/entrez SP - 936 EP - 41 JF - Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA JO - Osteoporos Int VL - 17 IS - 6 N2 - INTRODUCTION: The purpose of this study was to evaluate parathyroid function at monthly intervals following the implantation of TheraCyte-encapsulated live human parathyroid cells into ovariectomized rats and to determine the effect on bone mineral density (BMD) 4 months after ovariectomy (3 months after implantation). METHODS: Parathyroid tissues were obtained from patients undergoing surgery for secondary hyperparathyroidism. In total, 21 Sprague-Dawley rats divided randomly into three groups were subjected to one of three treatments: (1) implanted with TheraCyte A-encapsulated 4x10(6) live parathyroid cells; (2) implanted with TheraCyte B-encapsulated 4x10(5) live parathyroid cells; (3) a sham operation; the control group. Rats were ovariectomized 1 month prior to the implantation of the TheraCyte. Blood was drawn at the time of implantation and at monthly intervals thereafter for 3 months to check the levels of calcium, phosphorus and intact parathyroid hormone (iPTH). The BMD of the lumbar spine (L1-L5) and of the left femoral bone was measured with dual-energy-X-ray absorptiometry (DEXA) 1 month after ovariectomy and 3 months after implantation of the TheraCyte (4 months after ovariectomy). RESULTS: We found that the viability ratio of cryopreserved tissues was between 55 and 79% after thawing. In the control group, the BMD of the lumbar spine (L1-L5) had not decreased significantly (p=0.237) nor had the BMD of the left femoral bone increased significantly (p=0.063) 3 months after implantation. In the TheraCyte A group, the BMD of both the lumbar spine (p=0.018) and left femoral bone (p=0.018) had increased significantly 3 months after implantation. In the TheraCyte B group, the BMD of both the lumbar spine (p=0.017) and the left femoral bone (p=0.025) had also increased significantly 3 months after implantation. Serum iPTH levels were higher in the TheraCyte A group than in the TheraCyte B group (p=0.006), and higher in the TheraCyte B group than in the control group (p=0.040). Serum calcium levels were not significantly higher in the TheraCyte group A than in the TheraCyte B group or in the control group. Serum phosphorus levels were not significantly different between the TheraCyte A and TheraCyte B groups. CONCLUSIONS: Implantation of TheraCyte A-encapsulated 4x10(5) live parathyroid cells and TheraCyte B-encapsulated 4x10(6) cells can increase the BMD of ovariectomized rats within 3 months of implantation. Neither cause high serum calcium and low phosphorus concentrations. SN - 0937-941X UR - https://www.unboundmedicine.com/medline/citation/16596462/Treatment_of_osteoporosis_with_TheraCyte_encapsulated_parathyroid_cells:_a_study_in_a_rat_model_ L2 - https://doi.org/10.1007/s00198-006-0080-7 DB - PRIME DP - Unbound Medicine ER -